Genoptix, Inc. to Announce Fourth Quarter and Full-Year 2009 Financial Results
CARLSBAD, Calif., Feb. 4 /PRNewswire-FirstCall/ -- Genoptix, Inc. (Nasdaq: GXDX), a provider of personalized diagnostic services, announced today that it expects to report its financial results for the fourth quarter and full-year 2009 after closing of the NASDAQ Global Select Market on Thursday, February 25, 2010.
A conference call hosted by President and CEO, Tina S. Nova, Ph.D., and other members of senior management will take place on the same day at 2:00pm PST (5:00pm EST) and will be webcast live on the Genoptix website.
To access the live conference call via phone, dial 866-578-5784 in the U.S. or Canada and 617-213-8056 for international callers. Please specify to the operator that you would like to join the "Genoptix Fourth Quarter and Full-Year 2009 Earnings Conference Call." The participant code for the call is 55554709. If you are unable to listen to the live webcast, a replay of the call will be available through Thursday, March 4, 2010. Interested parties can access the rebroadcast by dialing 1-888-286-8010 or 1-617-801-6888 internationally and entering the reservation number 41371647.
The conference call will be webcast live on the Internet and is accessible through the "Investors" section of the Genoptix website at www.genoptix.com, or by accessing the external website, www.fulldisclosure.com. To participate in the webcast, please connect to the Genoptix website several minutes prior to the start time to register, download and install any necessary software that may be required. An online replay is planned to follow shortly after and will be available until Thursday, March 4, 2010.
About Genoptix, Inc.
Genoptix is a leading specialized laboratory service provider focused on delivering personalized and comprehensive diagnostic services to its physician customers, community-based hematologists and oncologists. On the forefront of personalized diagnostic services, Genoptix's highly trained group of hematopathologists utilize sophisticated technology to provide integrated testing and actionable diagnostic reports. Its primary diagnostic services are designed to optimize the care of patients suffering from hematomalignancies, or cancers of the blood and bone marrow, including leukemia and lymphoma. Founded in 1999, Genoptix completed its initial public offering in November 2007 and is headquartered in Carlsbad, California. For more information, please visit www.genoptix.com.
This press release may contain forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements. Genoptix disclaims, however, any intent or obligation to update these forward-looking statements.
SOURCE Genoptix, Inc.